Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023 08:00 ET
|
Ovid Therapeutics Inc.
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to OvidOvid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash...
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
October 10, 2023 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
September 26, 2023 07:30 ET
|
Ovid Therapeutics Inc.
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023 07:30 ET
|
Ovid Therapeutics Inc.
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
August 30, 2023 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
August 04, 2023 08:00 ET
|
Ovid Therapeutics Inc.
Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment and initiated collaboration with...
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 01, 2023 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
June 28, 2023 08:00 ET
|
Ovid Therapeutics Inc.
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander...
Ovid Therapeutics Added to Russell 3000® Index
June 26, 2023 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 05, 2023 07:30 ET
|
Ovid Therapeutics Inc.
Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseasesLong-term data supporting soticlestat safety, tolerability and seizure-reduction...